go-v.orgdoi

The cost of hospital treatment of advanced stage lung cancer patients in a developing South East European country

Jelena Perin, Bojan Zarić, Jelica Eremić-Đođić, Z POTIC, Marijela Potić, Vanesa Sekeruš, Styliani Laskou, Charilaos Koulouris, Athanasios Katsaounis, Efstathios Theodoros Pavlidis, Stylianos Mantalovas, Dimitrios Giannakidis, Nikolaos Michalopoulos, Aikaterini Amaniti, Fotis Konstantinou, Chrysanthi Sardeli, Yunye Ning, Hui Rong Shi, Haidong Huang, Chong Bai · Journal of Cancer · 2018

  • DOI 10.7150/jca.26278
  • Publisher Ivyspring International Publisher
  • Type article
  • Issued 2018

Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.

Journal of Cancer · Ivyspring International Publisher · article · 2018

Abstract

Assessing the lung cancer treatment costs is necessary in order to estimate the budget impact of new interventions and therapeutic innovations. However, there are few studies regarding the use of resources and costs associated with treatment of lung cancer patients, not only in Serbia, but internationally. The aim of this paper was to assess the hospital costs of diagnosing and treating patients with stage IIIB and IV non-small cell lung cancer. Analysis of costs of care, services, medications and medical supplies, as well as of total hospital costs, was performed. Patients diagnosed with stage IIIB or IV NSCLC in the Institute during the year 2013 were enrolled in the study.

A total of 187 patients with stage IIIB or IV NSCLC were analyzed. Total hospital costs were 506.970€, of which nearly two thirds was accounted to costs of services and medications. The mean cost per patient with adenocarcinoma was 3.075€, and for squamous cell lung carcinoma patient 1.943€. Statistically significant difference was shown when comparing mean hospital costs between patients in stage IIIB and stage IV adenocarcinoma, where this cost is higher in patients with stage IIIB. Mean hospital cost per female patient was nearly double as high that of the male patients, although without statistically significant difference.

The mean cost for all adenocarcinoma patients was 1.317€, and for only four patients treated with TKI therapy 21.233€. This cost analysis could provide useful information in terms of budget impact of different lung cancer treatments and innovations in Serbia and corresponding developing countries.

Open the resolved locator · 10.7150/jca.26278

Metadata licence: OpenAlex metadata (CC0)

Registry
OpenAlex DOI index + API
Fetched
2026-11-19 21:29 UTC
Cache state
not cached yet (bulk-index+openalex)
Locator
https://www.jcancer.org/v09p3038.htm
Metadata licence
OpenAlex metadata (CC0)
Scope
Metadata as returned by the resolver; abstracts are never generated here.